Windtree Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Warrington PA United States (1992)

Organization Overview

First Clinical Trial
2000
NCT00004500
First Marketed Drug
2012
lucinactant (surfaxin)
First NDA Approval
2012
lucinactant (surfaxin)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Discovery Laboratories | WINDTREE THERAP | Windtree Therapeutics | Windtree Therapeutics, Inc.

Active Ingredients

Marketed Drugs (1)

lucinactant (surfaxin) (2012 NDA)

Drugs in Phase 4 Trials (1)

Key: Windtree Therapeutics (0) Acquired (1)

treprostinil (remodulin) (2 trials)

Drugs in Phase 3 Trials (4)

colfosceril palmitate (8 trials)

palmitic acid (8 trials)

phosphatidylglycerol (8 trials)

sinapultide (8 trials)

Drugs in Phase 2 Trials (4)

Key: Windtree Therapeutics (1) Acquired (3)

istaroxime (4 trials)

losartan (cozaar) (1 trial)

lucinactant (surfaxin) (3 trials)

rostafuroxin (1 trial)

Drugs in Phase 1 Trials (1)

Key: Windtree Therapeutics (0) Acquired (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Birth Weight (Phase 2)

Bronchopulmonary Dysplasia (Phase 2)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Lung Diseases (Phase 2)

Lung Injury (Phase 2)

Meconium Aspiration Syndrome (Phase 3)

Premature Birth (Phase 2)

Pulmonary Fibrosis (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Respiratory Insufficiency (Phase 2)

Shock (Phase 2)

Shock, Cardiogenic (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 10